Heparin 1000 Units / mL – Quick Reference
| Feature | Details |
|---------|---------|
| Drug class | Unfractionated heparin (UFH) – anticoagulant |
| Form | Parenteral solution, ready‑to‑use vial (often in 10 mL or 5 mL ampoules) |
| Concentration | 1000 IU per mL (1 IU = 0.001 mL in most commercial preparations) |
| Typical volume | 5 mL vial = 5,000 IU; 10 mL vial = 10,000 IU |
| Common indications | • Prophylaxis or treatment of venous thromboembolism (VTE)
• Acute coronary syndromes (e.g., unstable angina, STEMI)
• Atrial fibrillation (for cardioversion)
• Periprocedural anticoagulation (cardiac cath, PCI, hemodialysis)
• Bridging anticoagulation around surgery |
| Typical dosing | • Prophylaxis (IV): 5,000 IU every 8–12 h (or 5000 IU BID in some settings)
• Treatment of VTE: 80 IU/kg IV bolus, then 18 IU/kg/h infusion (target aPTT 1.5–2.5× baseline)
• Acute coronary syndrome: 70 IU/kg IV bolus, then 12 IU/kg/h infusion (target aPTT 1.5–2.5×)
• Cardioversion: 120–150 IU/kg IV bolus 30 min before procedure
• Periprocedural: 10,000–15,000 IU IV bolus 5 min before procedure, then 5000 IU/8–12 h as needed |
| Administration | • Dilute 1–5 mL vial in 100 mL 0.9 % NaCl or 5 % dextrose for IV infusion
• Use a dedicated infusion set; avoid mixing with other drugs in the same line
• For subcutaneous injections, use a separate syringe and needle |
| Monitoring | • aPTT (or ACT in cardiac cath) 1–2 h after IV bolus, then 4–6 h after dose change
• Platelet count daily if prolonged therapy (>5 days) to screen for heparin‑induced thrombocytopenia (HIT) |
| Contraindications | • Active major bleeding or high bleeding risk
• Severe thrombocytopenia (platelets < 50 ×10^9/L)
• Known allergy to heparin or LMWH |
| Warnings & Precautions | • Heparin‑induced thrombocytopenia (HIT) – monitor for a 30–50 % drop in platelets 5–10 days after initiation
• Bleeding risk with concomitant antiplatelet, NSAID, warfarin, or DOAC use
• Use with caution in patients with renal dysfunction (UFH is cleared by the liver, but monitoring is essential) |
| Drug interactions | • Antiplatelet agents (clopidogrel, aspirin) ↑ bleeding risk
• Warfarin, DOACs, NSAIDs, steroids, and many herbal supplements may potentiate anticoagulation
• GPIIb/IIIa inhibitors (e.g., abciximab) require careful overlap |
| Side effects | • Bleeding (major or minor)
• Thrombocytopenia (HIT)
• Osteoporosis with long‑term use
• Skin at injection site (if SC) – erythema, induration |
| Storage | • Store at 2–8 °C (refrigerated)
• Protect from light; avoid freezing
• Use within 14 days after opening (manufacturer’s instructions) |
| Reconstitution (if not pre‑filled) | • 1 mL of vial → 10 mL 0.9 % NaCl (for IV) or 5 % dextrose (for SC)
• Mix gently; do not shake vigorously |
---
Quick Tips
- Dose adjustments: For patients < 50 kg or with renal/hepatic impairment, use lower loading doses and lower infusion rates; always confirm aPTT targets.
- Switching to LMWH: If prolonged therapy is anticipated (> 5 days) or if the patient has a high risk of HIT, consider low‑molecular‑weight heparin (LMWH) as an alternative.
- Emergency reversal: Protamine sulfate 1 mg per 1000 IU of heparin (up to 25 mg) can reverse anticoagulation in emergencies.
- Documentation: Record loading dose, infusion rate, aPTT/ACT values, platelet counts, and any adverse events in the medication chart.
---
If you need more specific guidance—such as dosing for a particular patient scenario, bridging schedules, or handling a suspected HIT—feel free to ask!